Drug maker Cipla is expected to report a whopping 47 percent growth in first quarter profit at Rs 433.4 crore compared to Rs 294.6 crore in the year-ago period, according to average of estimates of analysts polled by CNBC-TV18. Profit growth may be led by other income, overall performance in topline and EBITDA.
In Q1FY15, other income declined 41 percent to Rs 40.39 crore, which impacted bottomline as well. The pharma company will announce its earnings on August 14.
Revenue is likely to increase 24.2 percent to Rs 3,378 crore in June quarter compared to Rs 2,720 crore in same quarter last fiscal, driven by export formulations.
Analysts expect export formulations (which contribute 50 percent to sales) growth at 25-30 percent led by supply of Nexium generic capsules to Teva while domestic business may be steady in Q1.
Operating profit (earnings before interest, depreciation and amortisation) may surge 32 percent year-on-year to Rs 714 crore and margin may expand 117 basis points to 21.1 percent in the quarter gone by.
Cipla, after its Q4FY15 earnings, said it expects 15 percent revenue growth and 150 basis points margin expansion.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
